Hualan vaccine can be purchased.
at 9: 3 am on February 18th, 222, Hualan Biovaccine Co., Ltd. (stock abbreviation: Hualan Vaccine, stock code: 3127) was successfully listed on the Growth Enterprise Market of Shenzhen Stock Exchange. The IPO plans to publicly issue no more than 4.1 million shares, with an issue price of 56.88 yuan/share and raised funds of 2.276 billion yuan. It is reported that this is the first A-share listed enterprise in Henan Province this year and the fifth A-share listed enterprise in Xinxiang City.
Hualan Vaccine was established in 25, which is a subsidiary of Hualan Bio, a A-share listed company, and it is also the first enterprise in Henan Province to be split and listed. Hualan Vaccine is mainly engaged in the production, research and development and sales of human vaccines. It is the first company in the world to develop influenza A (H1N1) vaccine, the first one in China to be approved to produce tetravalent influenza vaccine for adults and children, and the only one in China to pass the WHO certification of influenza vaccine. The production scale of influenza vaccine ranks first in Asia.
In p>218-22, the proportion of annual batch issuance of Hualan vaccine influenza vaccine to domestic batch issuance of influenza vaccine was 52.77%, 42.2% and 4.16% respectively, ranking first in the industry.
on February 8, 222, according to the announcement of the exchange, Hualan vaccine was purchased today, with the purchase code of 3127 and the issue price of 56.88 yuan/share. The top-level purchase needs to be matched with a market value of 65, yuan. Kun Heng Shun Wei announced the winning number. China Catalyst and Hefu China announced the winning rate, and the final winning rate of online issuance was .312% and .449% respectively.
The office address of Hualan Biological Vaccine Co., Ltd. is located in Xinxiang, the capital of battery industry in China, with No.1 attached to No.1 Hualan Avenue, Xinxiang City, Henan Province. It was incorporated in Xinxiang Administration for Industry and Commerce on November 9, 25 with a registered capital of 1 million RMB. During the 16 years of the company's development, we have always provided customers with good products and technical support and sound after-sales service. Our company mainly engaged in the production of various types.
subscription refers to the behavior of investors applying to purchase fund shares during the existence of the fund after its establishment and during the period of subscription opening. After the fund closed period, if you apply to buy an open-end fund, it is customarily called fund subscription to distinguish the subscription during the issuance period. The subscription of the fund is to buy. Listed closed-end funds are bought in the same way as ordinary stocks. Open-end fund is the amount you want to purchase, divided by the net value of the fund on the day of purchase, to get the number of buying units.